Clinical Trial Details
Back to clinical trials
Phase IInterventional
An Open-Label Evaluation Phase 1 Trial of the Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults With Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia
Protocol: STUDY00002843NCT: NCT04872478
Overview
Primary Objective:
- To evaluate the safety and tolerability and establish the Recommended Phase 2 dose (RP2D) of orally-administered (PO) MRX-2843 in patients with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia.
Secondary Objectives:
- To evaluate the pharmacokinetics and efficacy of MRX-2843 in patients with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia
